Last reviewed · How we verify
NCT06610799
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase 1 trial testing IBI363 in IBI363 + Chemotherapy in 40 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Xiangdong Cheng |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 15 October 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- IBI363 — full drug profile →
Conditions studied
- IBI363 + Chemotherapy — all drugs for IBI363 + Chemotherapy →
Sponsor
Xiangdong Cheng — full company profile →
Who can join
Adults 18 to 75, any sex, with IBI363 + Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, et al · · 2025 · cited 12× · PMID 40565299 · DOI 10.3390/ijms26125838
Verify or expand the search:
- PubMed search for NCT06610799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IBI363
Trials testing the same drug.
- NCT07402070 — IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07307053 — Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) · Phase 1, PHASE2 · not yet recruiting
- NCT07217301 — IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed · Phase 3 · recruiting
- NCT07122687 — IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage · Phase 2 · recruiting
- NCT06797297 — A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectabl · Phase 2 · recruiting
Other recruiting trials for IBI363 + Chemotherapy
Currently open trials in the same condition.
- NCT07325630 — Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer · Phase 2 · recruiting
Other Xiangdong Cheng trials
Trials by the same sponsor.
- NCT07068516 — Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer · Phase 3 · not yet recruiting
- NCT06766305 — QL1706 Combined With SOX Used in Theperioperative Treatment · Phase 1, PHASE2 · recruiting
- NCT06614179 — A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established · recruiting
- NCT06374901 — Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. · Phase 2 · not yet recruiting
- NCT06642857 — Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastr · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06610799 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangdong Cheng
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06610799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing